AirXpanders' AeroForm® to Be Featured at ASPS Plastic Surgery Meeting 2015

Study investigators to present clinical results at world's largest gathering of plastic surgeons

Oct 15, 2015, 09:05 ET from AirXpanders Inc.

BOSTON and PALO ALTO, Calif., Oct. 15, 2015 /PRNewswire/ -- AirXpanders Inc., a company developing novel technology for women who require tissue expansion for breast reconstruction following a mastectomy, announced today that its tissue expander will be featured in two presentations at the American Society of Plastic Surgeons (ASPS) Plastic Surgery: The Meeting 2015, October 16-20 at the Boston Convention and Exhibition Center (booth #1120). The ASPS is the largest specialty plastic surgery organization in the world. With more than 7,000 members, the ASPS comprises 94 percent of all board-certified plastic surgeons in the United States.

AirXpanders' AeroForm device is an injection-free, patient-controlled tissue expansion system that is CE Marked, approved in Australia and has concluded its pivotal investigation in the United States. At The Meeting, Dr. Jeffrey Ascherman (Columbia University, New York, New York) will report on the results of AirXpanders' XPAND U.S. pivotal trial, which compared AeroForm to saline tissue expansion in a prospective, multi-center, randomized, controlled study. At the Residents Day Program immediately preceding The Meeting, Dr. Kamakshi Zeidler (Los Gatos, California) will present information detailing the use of AeroForm and clinical results to plastic surgery residents.

AirXpanders Presentations by Date and Time:

AeroForm, the New Gold Standard in 2-stage Tissue Expansion
Kamakshi Zeidler, MD
Friday, October 16, 2015
11:05 a.m. - 11:45 a.m. EDT
Residents Day Program
Boston Convention and Exhibition Center

AeroForm vs Saline Tissue Expansion in Breast Reconstruction: A Prospective Multi-Center Randomized Controlled Clinical Study
Jeffrey Ascherman, MD
Sunday, October 18, 2015
10:30 a.m. - 11:45 a.m. EDT
Scientific Paper Session: Breast 1
Boston Convention and Exhibition Center

"We are honored to have two papers accepted at such a prestigious meeting," said Scott Dodson, AirXpanders president and CEO. "Producing Level I evidence is not an easy task to accomplish; however, we are committed to delivering exceptional data in support of our technology. We recently reported that our XPAND U.S. pivotal study, the first and only randomized controlled trial involving the use of tissue expanders, has concluded and we met our primary endpoint. We look forward to hearing from the FDA on its review of our 510(k) submission."

For more information about AeroForm, please visit AirXpanders at ASPS Plastic Surgery: The Meeting in booth #1120.

About AirXpanders

AirXpanders Inc. ( is a tissue expansion company focused on the area of breast reconstruction. By employing a revolutionary patient-controlled expander, activated by a wireless remote control, the often painful process of reclaiming one's body after cancer can potentially be eased with this needle-free technology. This technology is easy to use and may enable the patient to proceed to a permanent implant much faster than the current standard of care. AirXpanders is a publically listed company on the Australian Stock Exchange under the symbol AXP and is backed by Vivo Ventures, GBS Venture Partners, Prolog Ventures, Heron Capital, Shalon Ventures, Correlation Ventures, Western Technology Investments and a number of leading investment firms in Australia, Hong Kong and Singapore. AirXpanders devices are not cleared or approved for use in the United States and are considered for investigational use only. AirXpanders is cleared for commercialization in Europe and in Australia.

Media Contact
Caitlin Nolan
(415) 512-0770

Logo -


SOURCE AirXpanders Inc.